Anthracyclines May Improve Survival in High-Risk Breast Cancer, But Risks Must Be Weighed - report from SABCS2024

Nan Chen, MD explains patients with early-stage, node-negative, hormone receptor positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:anthracyclines-may-improve-survival-high-risk-breast-cancer-risks-must-be-weighed